Challenges in diagnosis and management of neutropenia upon exposure to immune-checkpoint inhibitors: meta-analysis of a rare immune-related adverse side effect
Abstract Background Cancer immunotherapy via immune-checkpoint inhibition (ICI) by antibodies against cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and cell death protein 1 (PD-1) have significantly improved the outcome of metastasized melanoma and of a rapidly increasing number of other canc...
Main Authors: | J. Boegeholz, C. S. Brueggen, C. Pauli, F. Dimitriou, E. Haralambieva, R. Dummer, M. G. Manz, C. C. Widmer |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-04-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12885-020-06763-y |
Similar Items
-
Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition
by: Abdul Rafeh Naqash, et al.
Published: (2019-07-01) -
Targeting immune checkpoints in hematological malignancies
by: Basit Salik, et al.
Published: (2020-08-01) -
Hematological Side Effects of Immune Checkpoint Inhibitors: The Example of Immune-Related Thrombocytopenia
by: Roser Calvo
Published: (2019-04-01) -
IMMUNE CHECKPOINT INHIBITORS AND RHEUMATIC ADVERSE EVENTS
by: Ioana Cretu, et al.
Published: (2018-12-01) -
Immune-mediated adverse events in immune checkpoint inhibitors therapy: literature review
by: Marina A. Lyadova, et al.
Published: (2021-08-01)